JP7817257B2 - ｍＲＮＡワクチンを送達するための脂質ナノ粒子 - Google Patents

ｍＲＮＡワクチンを送達するための脂質ナノ粒子

Info

Publication number
JP7817257B2
JP7817257B2 JP2023526888A JP2023526888A JP7817257B2 JP 7817257 B2 JP7817257 B2 JP 7817257B2 JP 2023526888 A JP2023526888 A JP 2023526888A JP 2023526888 A JP2023526888 A JP 2023526888A JP 7817257 B2 JP7817257 B2 JP 7817257B2
Authority
JP
Japan
Prior art keywords
mrna
composition
antigen
lipid
lnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023526888A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022099003A5 (https=
JP2023550600A5 (https=
JP2023550600A (ja
Inventor
ダニロ・カシミロ
サッダ・チブクラ
フランク・デローザ
アニュシャ・ディアス
レベッカ・エル・ゴールドマン
ハーディップ・ラージェッシュバイ・ゴパニ
キリル・カルニン
シュリーラン・カルヴィ
アサッド・カーンムハマド
プリヤール・パテル
ティモシー・プリトニク
アシシュ・エル・サロード
ティモシー・ティビッツ
カン・アン・トラン
ナタリア・バルガス・モントヤ
アンジェラ・リーン・ボーリュー
Original Assignee
サノフィ パスツール インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ パスツール インコーポレイテッド filed Critical サノフィ パスツール インコーポレイテッド
Priority claimed from PCT/US2021/058250 external-priority patent/WO2022099003A1/en
Publication of JP2023550600A publication Critical patent/JP2023550600A/ja
Publication of JPWO2022099003A5 publication Critical patent/JPWO2022099003A5/ja
Publication of JP2023550600A5 publication Critical patent/JP2023550600A5/ja
Application granted granted Critical
Publication of JP7817257B2 publication Critical patent/JP7817257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023526888A 2020-11-06 2021-11-05 ｍＲＮＡワクチンを送達するための脂質ナノ粒子 Active JP7817257B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063110965P 2020-11-06 2020-11-06
US63/110,965 2020-11-06
US202163212523P 2021-06-18 2021-06-18
US63/212,523 2021-06-18
EP21315198 2021-10-13
EP21315198.8 2021-10-13
PCT/US2021/058250 WO2022099003A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Publications (4)

Publication Number Publication Date
JP2023550600A JP2023550600A (ja) 2023-12-04
JPWO2022099003A5 JPWO2022099003A5 (https=) 2025-06-17
JP2023550600A5 JP2023550600A5 (https=) 2025-06-17
JP7817257B2 true JP7817257B2 (ja) 2026-02-18

Family

ID=86184333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526888A Active JP7817257B2 (ja) 2020-11-06 2021-11-05 ｍＲＮＡワクチンを送達するための脂質ナノ粒子

Country Status (9)

Country Link
EP (1) EP4240335A1 (https=)
JP (1) JP7817257B2 (https=)
KR (1) KR20230104223A (https=)
CN (1) CN116406299A (https=)
AU (1) AU2021374976A1 (https=)
CA (1) CA3194325A1 (https=)
CO (1) CO2023005218A2 (https=)
IL (1) IL302631A (https=)
MX (1) MX2023005203A (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
EP4612301A1 (en) * 2022-11-03 2025-09-10 ModernaTX, Inc. Chemical stability of mrna
CN118021957A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
CN118021956A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
CN120053395A (zh) * 2023-11-30 2025-05-30 苏州维益生物科技有限公司 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法
CN118725043B (zh) * 2024-06-27 2025-12-05 中国人民解放军陆军军医大学 用于递送核酸的多肽-脂质组合物及其应用和mRNA疫苗
CN119746089B (zh) * 2025-03-07 2025-06-13 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
CN121466311A (zh) * 2026-01-09 2026-02-06 羿美诚健(上海)生物医药有限公司 一种脂质组合物及其在核酸递送中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148247A1 (en) 2014-03-24 2015-10-01 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
JP2018519285A (ja) 2015-06-19 2018-07-19 マサチューセッツ インスティテュート オブ テクノロジー アルケニル置換２，５−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用
WO2022221688A1 (en) 2021-04-15 2022-10-20 Translate Bio, Inc. "good"buffer-based cationic lipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148247A1 (en) 2014-03-24 2015-10-01 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
JP2018519285A (ja) 2015-06-19 2018-07-19 マサチューセッツ インスティテュート オブ テクノロジー アルケニル置換２，５−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用
WO2022221688A1 (en) 2021-04-15 2022-10-20 Translate Bio, Inc. "good"buffer-based cationic lipids

Also Published As

Publication number Publication date
MX2023005203A (es) 2023-07-13
IL302631A (en) 2023-07-01
CA3194325A1 (en) 2022-05-12
AU2021374976A1 (en) 2023-06-29
CN116406299A (zh) 2023-07-07
CO2023005218A2 (es) 2023-05-19
KR20230104223A (ko) 2023-07-07
JP2023550600A (ja) 2023-12-04
EP4240335A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
US12239735B2 (en) Lipid nanoparticles for delivering mRNA vaccines
JP7817257B2 (ja) ｍＲＮＡワクチンを送達するための脂質ナノ粒子
US20230043128A1 (en) Multivalent influenza vaccines
US20230310571A1 (en) Human metapneumovirus vaccines
JP2024542085A (ja) 呼吸器合胞体ウイルスｒｎａワクチン
WO2025003756A2 (en) Multivalent influenza mrna vaccines
TW202527960A (zh) 經修飾ｂ型流感血球凝集素多肽及核酸及其用途
CN117580568A (zh) 多价流感疫苗
RU2860421C2 (ru) ЛИПИДНЫЕ НАНОЧАСТИЦЫ ДЛЯ ДОСТАВКИ mRNA-ВАКЦИНЫ
HK40096671A (zh) 用於递送mrna疫苗的脂质纳米颗粒
WO2024131726A1 (zh) 一种广谱流感mRNA疫苗
TW202508620A (zh) 呼吸道mrna組合疫苗
WO2026027730A1 (en) Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241031

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260205

R150 Certificate of patent or registration of utility model

Ref document number: 7817257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533